Ipratropium Enfants Arrow (Ipratropium Bromide Anhydrous)

Ipratropium bromide blocks muscarinic M3 receptors on airway smooth muscle, preventing acetylcholine‑mediated contraction. This antagonism stops the bronchoconstrictive signal, leading to relaxation of the bronchial muscles, increased airway diameter, and improved airflow in obstructive lung conditions.

The specific dose and frequency are determined by the prescribing clinician based on the patient’s age, weight, disease severity, and response to therapy. Healthcare providers follow local prescribing guidelines and may adjust the regimen according to clinical need.

Safety data for ipratropium bromide during pregnancy and lactation are limited. The product should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where applicable) and any necessary import documentation.

The primary alternative to ipratropium is a short‑acting beta‑2 agonist such as albuterol, which works by stimulating bronchial smooth‑muscle relaxation via adrenergic receptors. Ipratropium provides bronchodilation through anticholinergic blockade and is often used in combination with beta‑agonists for additive effect. Long‑acting anticholinergics like tiotropium offer prolonged action but are generally reserved for adult maintenance therapy.

Store the product at room temperature, preferably below 25 °C, in its original packaging. Protect it from moisture, direct sunlight, and extreme temperatures. Do not freeze the solution, and keep the container tightly closed when not in use to maintain sterility.

The medication is delivered by inhalation, typically using a nebulizer or a metered‑dose inhaler (MDI) device designed for pediatric use. The patient inhales the mist or aerosol directly into the lungs as instructed by a healthcare professional, ensuring proper technique to achieve optimal drug deposition.

Serious adverse events, although rare, include urinary retention, acute angle‑closure glaucoma, severe allergic reactions such as anaphylaxis, paradoxical bronchospasm, and significant tachycardia. Patients should be instructed to seek immediate medical attention if they experience eye pain, visual changes, difficulty urinating, swelling of the face or throat, or sudden worsening of breathing.

Ipratropium Enfants Arrow is contraindicated in patients with known hypersensitivity to ipratropium bromide or any formulation excipients. It should be used with caution, or avoided, in individuals with narrow‑angle glaucoma, severe urinary retention, or significant prostatic hypertrophy, as the anticholinergic effects may exacerbate these conditions.